The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
ICICI Direct gives a preview on the earnings narrative for Q3FY22
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
The stability is led by healthy demand in the domestic and emerging markets
This surpasses the number of approvals supported in 2020
Subscribe To Our Newsletter & Stay Updated
